These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 19916992

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2- ANRS Study Group.
    Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
    [Abstract] [Full Text] [Related]

  • 3. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
    Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D, Glue PW.
    Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
    [Abstract] [Full Text] [Related]

  • 4. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
    Khaliq Y, Gallicano K, Seguin I, Fyke K, Carignan G, Bulman D, Badley A, Cameron DW.
    Br J Clin Pharmacol; 2000 Aug; 50(2):108-15. PubMed ID: 10930962
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.
    Sheehan NL, van Heeswijk RP, Foster BC, Akhtar H, Singhal N, Seguin I, DelBalso L, Bourbeau M, Chauhan BM, Boulassel MR, Burger DM, Lalonde RG, Cameron DW.
    Molecules; 2012 Jan 12; 17(1):688-702. PubMed ID: 22241465
    [Abstract] [Full Text] [Related]

  • 7. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
    Burger DM, Schwietert HR, Colbers EP, Becker M.
    Br J Clin Pharmacol; 2006 Aug 12; 62(2):250-2. PubMed ID: 16842404
    [No Abstract] [Full Text] [Related]

  • 8. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
    van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW.
    Clin Pharmacol Ther; 2004 Dec 12; 76(6):588-97. PubMed ID: 15592330
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.
    Antimicrob Agents Chemother; 2006 Jun 12; 50(6):2079-86. PubMed ID: 16723569
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.
    Antivir Ther; 2004 Feb 12; 9(1):77-84. PubMed ID: 15040539
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
    Regazzi M, Maserati R, Villani P, Cusato M, Zucchi P, Briganti E, Roda R, Sacchelli L, Gatti F, Delle Foglie P, Nardini G, Fabris P, Mori F, Castelli P, Testa L.
    Antimicrob Agents Chemother; 2005 Feb 12; 49(2):643-9. PubMed ID: 15673746
    [Abstract] [Full Text] [Related]

  • 16. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
    Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA.
    AIDS; 2001 May 25; 15(8):991-8. PubMed ID: 11399981
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.
    la Porte CJ, de Graaff-Teulen MJ, Colbers EP, Voncken DS, Ibanez SM, Koopmans PP, Hekster YA, Burger DM.
    Br J Clin Pharmacol; 2004 Dec 25; 58(6):632-40. PubMed ID: 15563361
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum.
    Eke AC, McCormack SA, Best BM, Stek AM, Wang J, Kreitchmann R, Shapiro D, Smith E, Mofenson LM, Capparelli EV, Mirochnick M, IMPAACT P1026s Protocol TeamDivision of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA..
    J Clin Pharmacol; 2019 Mar 25; 59(3):386-393. PubMed ID: 30358179
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.